922175-70-0 Usage
Uses
Used in Biomedicine:
CYCLO(RGDFK(SAA)) is used as a therapeutic agent for its potential to bind to integrin receptors, which are involved in cell adhesion and signaling. This property makes it a promising candidate for the development of drugs targeting various diseases and conditions.
Used in Drug Development:
CYCLO(RGDFK(SAA)) is used as a lead compound in the development of new drugs, particularly those aimed at treating conditions related to cell adhesion and signaling. Its ability to bind to integrin receptors and its potential anti-inflammatory properties make it a valuable asset in the search for novel therapeutic agents.
Used in Anti-inflammatory Applications:
CYCLO(RGDFK(SAA)) is used as an anti-inflammatory agent due to the presence of the SAA sequence, which is known to be involved in the acute phase response to inflammation. This property suggests that the peptide may be effective in treating inflammatory conditions and modulating the immune response.
Used in Pharmaceutical Research:
CYCLO(RGDFK(SAA)) is used as a research tool in pharmaceutical research to study the mechanisms of cell adhesion and signaling, as well as the role of integrin receptors in various biological processes. Its cyclic structure and potential therapeutic applications make it an attractive compound for further investigation and development.
Check Digit Verification of cas no
The CAS Registry Mumber 922175-70-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,2,2,1,7 and 5 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 922175-70:
(8*9)+(7*2)+(6*2)+(5*1)+(4*7)+(3*5)+(2*7)+(1*0)=160
160 % 10 = 0
So 922175-70-0 is a valid CAS Registry Number.
922175-70-0Relevant articles and documents
CLICK CHEMISTRY-DERIVED CYCLOPEPTIDE DERIVATIVES AS IMAGING AGENTS FOR INTEGRINS
-
Page/Page column 5, (2008/06/13)
The present application is directed to radiolabeled cyclic polypeptides, pharmaceutical compositions comprising radiolabeled cyclic polypeptides, and methods of using the radiolabeled cyclic polypeptides. Such polypeptides can be used in imaging studies,
